不同风险组和治疗分配概率在随机试验子组分析中的作用
Vadim Lesan1, Vlada Odaie2, Cristian Munteanu3
1Hematology and Oncology Department, Saarland University Hospital, Homburg, Germany.
Hematological oncology
|August 16, 2025
概括
追溯子组分析可能会导致危险比率 (HR) 估计偏差,特别是在不平衡的患者群体中. 谨慎的试验设计至关重要,以避免分组和治疗效应之间的误导性相关性.
科学领域:
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
- 流行病学 流行病学
背景情况:
- 追溯子组分析在临床研究中很常见.
- 在治疗手臂之间不平衡的患者分布可能会带来挑战.
- 在子组中估计危险比率 (HRs) 需要仔细考虑潜在的偏差.
研究的目的:
- 在回顾性小组分析中,量化患者分布不平衡所带来的偏差.
- 为了证明危险比率 (HRs) 如何随着潜在风险组人群变化而变化.
- 突出 robust 临床试验设计在减轻偏差方面的重要性.
主要方法:
- 进行蒙特卡洛模拟.
- 进行了1000次模拟试验.
- 系统地改变潜在风险组群体.
主要成果:
- 追溯子组分析可以在危险比率 (HR) 估计中引入显著的偏差.
- 不平衡的患者分布和不平等的风险组合扭曲了HR的有效性.
- 危险比率会随着潜在风险群体人口的变化而有系统的变化.
结论:
- 在从回顾性子组分析中解释HR时需要谨慎.
- 偏见可能导致分组分类和治疗效应之间的误导性相关性.
- 强大的试验设计对于准确的治疗效果估计至关重要.
相关概念视频
Randomized Experiments
7.2K
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
Simple randomization
Simple...
7.2K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
Hazard Ratio
244
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
244
Comparing the Survival Analysis of Two or More Groups
286
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
286
Group Design
9.6K
The most basic experimental design involves two groups: the experimental group and the control group. The two groups are designed to be the same except for one difference— experimental manipulation. The experimental group gets the experimental manipulation—that is, the treatment or variable being tested—and the control group does not. Since experimental manipulation is the only difference between the experimental and control groups, we can be sure that any differences between...
9.6K
Strategies for Assessing and Addressing Confounding
155
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
155


